Last Updated : April 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| TBC | fruquintinib | Metastatic colorectal cancer (mCRC) | Pending | |||
| TBC | exagamglogene autotemcel | Transfusion-dependent β-thalassemia | Pending | |||
| TBC | exagamglogene autotemcel | Sickle cell disease (SCD) | Pending | |||
| TBC | filgrastim | Prevention or treatment of neutropenia in various indications | Cancelled | |||
| TBC | filgrastim | Cancelled | ||||
| TBC | Darunavir / cobicistat | HIV infection | Withdrawn | |||
| TBC | abaloparatide | Osteoporosis, postmenopausal women | Withdrawn | |||
| TBC | tirzepatide | Diabetes mellitus, type 2 | Cancelled | |||
| TBC | daprodustat | Anemia due to chronic kidney disease | Withdrawn | |||
| TBC | ferumoxytol | Iron deficiency anemia | Withdrawn |
Last Updated : April 16, 2024